ACE-031

What is ACE-031?

ACE-031, also called ramatercept, is an engineered protein designed to block myostatin, the body's main brake on muscle growth. It was developed by the US biotech company Acceleron Pharma as a potential treatment for muscle-wasting diseases, with Duchenne muscular dystrophy as the lead target.

It is a large fusion protein of about 78,000 daltons, not a short peptide. It joins the outer, ligand-binding part of the activin receptor type IIB to the Fc tail of a human antibody.¹

Clinical development stopped after a trial in boys with Duchenne was halted over bleeding-related side effects. ACE-031 was never approved anywhere. It still circulates in bodybuilding and research-chemical markets, where it is sold as a muscle builder, and it is banned in sport.

The interest in myostatin is easy to understand. Animals born without working myostatin, including certain cattle breeds and laboratory mice, carry far more muscle than normal. That observation made myostatin one of the most pursued targets for muscle-wasting diseases, and ACE-031 was among the first drugs against it to reach human testing.

How ACE-031 works

Muscle size is held in check by signaling proteins, the best known being myostatin. Myostatin docks on a receptor on muscle cells and tells them to stop growing. ACE-031 works as a decoy. It floats in the blood looking like that receptor, grabs myostatin and related proteins first, and keeps them from reaching the real receptor. With the brake released, muscle can grow.

Technically, ACE-031 is a soluble ActRIIB-Fc fusion protein. ActRIIB is a shared receptor for several TGF-beta family ligands, including myostatin (GDF-8), activins and GDF-11, which signal through Smad2/3.² That breadth is the drug's main problem. Some of the same ligands help regulate blood vessel maintenance and blood cell production, so trapping them affects tissues well beyond muscle. Later drugs in this family were engineered to bind a narrower set of ligands, and two of them, luspatercept and sotatercept, are now approved for anemia and pulmonary arterial hypertension rather than for muscle.²

What the research shows on ACE-031

The best human data come from two small, placebo-controlled trials, both sponsored by the developer.

In a single-dose study, 48 healthy postmenopausal women received one injection of ACE-031 or placebo. At the highest dose, lean body mass rose by an average of 3.3% and thigh muscle volume by 5.1% at day 29, both statistically significant. Blood markers also suggested effects on bone and fat metabolism. The drug's half-life was 10 to 15 days, and it was generally well tolerated in that short study.³

The second trial gave repeated doses every two to four weeks to ambulatory boys with Duchenne muscular dystrophy. The study was stopped after the second dosing group because of nosebleeds and telangiectasias, small dilated blood vessels in the skin and gums. Before it stopped, the treated boys showed trends toward more lean mass, higher bone density, less fat and better preserved walking distance on the six-minute walk test compared with placebo. None of these trends reached statistical significance.¹

Those are the limits. The trials were small and short, the efficacy findings in Duchenne were not statistically significant, and no study measured whether the extra muscle translated into lasting strength or function. Healthy-volunteer gains after a single dose tell us the drug is biologically active, not that it is useful or safe to take repeatedly.

Studied for: Muscular dystrophy research (discontinued), Muscle mass research.

ACE-031 reference data

ACE-031 dosage in published research

How ACE-031 is used in practice

There is no clinical use. ACE-031 is not available through doctors, telehealth services or compounding pharmacies in the US. What exists is a gray market of vials labeled ACE-031, sold online for research and bought mainly by bodybuilders.

That market has a basic credibility problem. ACE-031 is a complex biologic made in living cells, folded correctly and paired with an antibody fragment. Producing it at pharmaceutical quality is expensive and technically demanding. It is unlikely that low-cost vials sold online reliably contain an intact, active fusion protein at the stated dose, and buyers have no practical way to check. Contaminants, wrong substances or inactive protein are all real possibilities.

Even a genuine product would raise questions the trials never answered. Repeated dosing over months was not completed in any study, so there is no reliable information on how effects build up or wear off over a typical gray-market cycle.

For athletes, myostatin inhibitors fall under the World Anti-Doping Agency's banned hormone and metabolic modulator category.

ACE-031 risks and side effects

The signature risks are vascular. In the Duchenne trial, nosebleeds and telangiectasias were the reason the study stopped, even though no serious or severe adverse events were reported.¹ Gum bleeding and skin redness have also been described, and injection-site redness was the main side effect in healthy volunteers.³

These effects fit the biology. The ligands ACE-031 traps also support normal blood vessel structure, so the side effects are a direct result of how the drug works rather than a quirk of one study.² That is a reason for particular caution in anyone with a bleeding disorder, vascular malformation or who takes anticoagulants or antiplatelet drugs.

Long-term effects are unknown because no one has taken it for long under study conditions. Effects on fertility, pregnancy, heart muscle and tendons have not been characterized. For gray-market products, add the risks of contamination, immune reactions to impurities and unknown dosing.

Reported side effects

Alternatives to ACE-031

For Duchenne muscular dystrophy, approved and better-studied options include corticosteroids such as prednisone and deflazacort, vamorolone, the histone deacetylase inhibitor givinostat, exon-skipping drugs for eligible mutations, and gene therapy for selected patients. Treatment decisions belong with a neuromuscular specialist.

For building muscle in healthy adults, progressive resistance training with adequate protein intake remains the most reliable approach. Men with diagnosed testosterone deficiency can be treated with testosterone under medical supervision. Other myostatin-pathway drugs, including antibodies against myostatin, remain investigational and are not substitutes available to the public.

Questions for a clinician

• What evidence applies to my situation, and at what level?
• What established alternatives should I consider first?
• What monitoring would be necessary, and how often?
• Can this be prescribed at all where I live, or only sold for research?